Pharma Business review is using cookies

ContinueLearn More
Close
September 21, 2018

Mylan, Fujifilm Kyowa get EC nod for Humira biosimilar Hulio

Mylan and Fujifilm Kyowa Kirin Biologics have secured marketing authorization from the European Commission (EC) for their Hulio, a biosimilar to AbbVie's Humira (adalimumab), for all indications.

Continue
Image: Head office of the European Commission. Photo: courtesy of Amio Cajander.
September 20, 2018

OBI Pharma’s OBI-3424 gets FDA orphan drug status to treat ALL

Image: FDA grants orphan drug designation to OBI Pharma’s OBI-3424 for the treatment of ALL. Photo: courtesy of The U.S. Food and Drug Administration/Wikipedia.org.
September 19, 2018

BeiGene selects GE’s KUBio facility to boost cancer drugs manufacturing capacity

Image: GE KUBio biomanufacturing facility for BeiGene. Photo: courtesy of General Electric.

Contracts

September 21, 2018

Opiant signs contract with BARDA to accelerate OPTN003 product development

Image: Opiant Pharmaceuticals has signed contract with BARDA to accelerate development of nasal nalmefene to treat opioid overdose. Photo: courtesy of Baitong333 / FreeDigitalPhotos.net.

BioCryst bags contract to supply RAPIVAB antiviral flu therapy doses to CDC

Data science company IXICO extends contract with biopharmaceutical firm

Abzena signs manufacturing and bioconjugation deal with Telix

Deals

Deals September 20, 2018

Grifols secures FTC’s conditional approval for Biotest US acquisition

Pharmaceutical Business Review

Allergan to buy clinical-stage biotechnology firm Bonti for $195m

Boehringer Ingelheim buys Austrian firm ViraTherapeutics for €210m

Carlyle buys minority stake in US CDMO Ambio from MVM Partners

Popular

  1. Norgine to commercialize Shield’s iron deficiency therapy in Europe, Australia and New Zealand
  2. AstraZeneca secures FDA approval for Lumoxiti to treat hairy cell leukaemia
  3. Shire’s Veyvondi secures approval in Europe for bleeding disorder
  4. Bristol-Myers plaque psoriasis drug BMS-986165 succeeds in phase 2 trial
  5. Gilead, Galapagos’ filgotinib succeeds in phase 3 rheumatoid arthritis study

Videos

Suppliers

Spotlight

Pharmaceutical Business Review
Novo Nordisk to slash 400 jobs in R&D restructuring
Pharmaceutical Business Review
ACCC clears merger of generic pharmaceutical firms Arrow and Apotex
Pharmaceutical Business Review
Boehringer Ingelheim buys Austrian firm ViraTherapeutics for €210m